Fletcher, Sean A.
Harmouch, Sabrina S.
Krimphove, Marieke J.
Cole, Alexander P.
Berg, Sebastian
Gild, Philipp
Preston, Mark A.
Sonpavde, Guru P.
Kibel, Adam S.
Sun, Maxine
Choueiri, Toni K.
Trinh, Quoc-Dien http://orcid.org/0000-0003-3857-9276
Funding for this research was provided by:
Brigham Research Institute Fund to Sustain Research Excellence
Bruce A. Beal and Robert L. Beal Surgical Fellowship
Genentech Bio-Oncology Career Development Award from the Conquer Cancer Foundation of the American Society of Clinical Oncology (10202)
Health Services Research pilot test grant from the Defense Health Agency
Clay Hamlin Young Investigator Award from the Prostate Cancer Foundation (16YOUN20)
Unrestricted Educational Grant from the Vattikuti Urology Institute
Article History
Received: 24 March 2018
Accepted: 8 June 2018
First Online: 14 June 2018
Compliance with ethical standards
:
: QDT reports honoraria from Bayer and Astellas and research funding from Intuitive Surgical. ASK reports consulting fees from Sanofi and Profound Medical; GPS is a consultant for BMS, Exelixis, Bayer, Sanofi, Pfizer, Novartis, Eisai, Janssen, Amgen, Astrazeneca, Merck, Genentech, Astellas/Agensys, and reports research support to institution from Bayer, Amgen, Boehringer-Ingelheim, Merck, Sanofi, Pfizer.
: We used completely de-identified data from the National Cancer Database. No identifiable humans were involved. Our study did not involve animals. Thus, our study was exempt from formal review by the Brigham and Women’s Hospital institutional review board.
: All patient data were de-identified/anonymous and collected from hospitals that gave their informed consent to collect this information for the database.